Hemostemix Inc (HEM) - Total Liabilities

Latest as of September 2025: CA$4.80 Million CAD ≈ $3.47 Million USD

Based on the latest financial reports, Hemostemix Inc (HEM) has total liabilities worth CA$4.80 Million CAD (≈ $3.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Hemostemix Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Hemostemix Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Hemostemix Inc to evaluate short-term liquidity relative to the company's equity base.

Hemostemix Inc Competitors by Total Liabilities

The table below lists competitors of Hemostemix Inc ranked by their total liabilities.

Company	Country	Total Liabilities
JATCORP LTD. F:3J2	Germany	€14.53 Million
Paulic Meunerie Sa PA:ALPAU	France	€10.66 Million
Elanor Investors Group AU:ENN	Australia	AU$619.30 Million
Metro Realty Tbk JK:MTSM	Indonesia	Rp20.44 Billion
Sipa Resources Ltd AU:SRI	Australia	AU$540.56K
Hays plc LSE:HAS	UK	GBX1.30 Billion
Home Pottery Public Company Limited BK:HPT	Thailand	฿93.80 Million
Pila Pharma AB ST:PILA	Sweden	Skr1.43 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Hemostemix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hemostemix Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.54	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hemostemix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hemostemix Inc (2013–2024)

The table below shows the annual total liabilities of Hemostemix Inc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$8.20 Million ≈ $5.93 Million	+6.65%
2023-12-31	CA$7.68 Million ≈ $5.56 Million	+6.23%
2022-12-31	CA$7.23 Million ≈ $5.23 Million	+23.73%
2021-12-31	CA$5.85 Million ≈ $4.23 Million	+70.87%
2020-12-31	CA$3.42 Million ≈ $2.48 Million	-17.54%
2019-12-31	CA$4.15 Million ≈ $3.00 Million	+253.31%
2018-12-31	CA$1.17 Million ≈ $849.58K	+152.68%
2017-12-31	CA$464.79K ≈ $336.22K	-87.40%
2016-12-31	CA$3.69 Million ≈ $2.67 Million	+492.45%
2015-12-31	CA$622.73K ≈ $450.47K	+12.87%
2014-12-31	CA$551.70K ≈ $399.09K	+127.05%
2013-12-31	CA$242.98K ≈ $175.77K	--

About Hemostemix Inc

V:HEM Canada Biotechnology

Market Cap

$6.82 Million

CA$9.42 Million CAD

Market Cap Rank

#27925 Global

#1220 in Canada

Share Price

CA$0.05

Change (1 day)

-9.09%

52-Week Range

CA$0.05 - CA$0.15

All Time High

CA$13.40